Home Newsfeeds Raymond James Downgrades Frontdoor to Market Perform

Raymond James Downgrades Frontdoor to Market Perform

Raymond James analyst Aaron Kessler downgrades Frontdoor (NASDAQ:FTDR) from Outperform to Market Perform.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Raymond James analyst Aaron Kessler downgrades Frontdoor (NASDAQ:FTDR) from Outperform to Market Perform.

Elon Musk’s Twitter Deal May Get Funding From South Korean SpaceX Backer Before Friday Deadline

By Shanthi Rexaline

October 25, 3:30 AM

Elon Musk could reportedly receive a helping hand from a South Korean financial services company as the Oct.

TSLA

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach To Treatment Of Uncontrolled Or Resistant Hypertension With Lorundrostat Data At AHA Scientific Sessions 2023

By Benzinga Newsdesk

November 11, 4:04 PM

– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone – – Excess aldosterone in patients

MLYS

Why Tonix Pharmaceuticals (TNXP) Stock Is Falling Sharply Today

By Henry Khederian

November 1, 10:58 AM

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower by 17% to $0.49 Wednesday morning. The company late Tuesday announced the topline results of a Phase 2 study for TNX-601 ER, a treatment for

TNXP